These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 35449015)

  • 21. Antiplatelet agents for chronic kidney disease.
    Palmer SC; Di Micco L; Razavian M; Craig JC; Perkovic V; Pellegrini F; Jardine MJ; Webster AC; Zoungas S; Strippoli GF
    Cochrane Database Syst Rev; 2013 Feb; (2):CD008834. PubMed ID: 23450589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
    Kalantzi KI; Ntalas IV; Chantzichristos VG; Tsoumani ME; Adamopoulos D; Asimakopoulos C; Bourdakis A; Darmanis P; Dimitriadou A; Gkiokas S; Ipeirotis K; Kitikidou K; Klonaris I; Kostaki A; Logothetis D; Mainas K; Mais T; Maragiannis A; Martiadou K; Mavronasos K; Michelongonas I; Mitropoulos D; Papadimitriou G; Papadopoulos A; Papaioakeim M; Sofillas K; Stabola S; Stefanakis E; Stergiou D; Thoma M; Zenetos A; Zisekas S; Goudevenos JA; Panagiotakos DB; Tselepis AD
    Curr Vasc Pharmacol; 2019; 17(6):635-643. PubMed ID: 29866011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
    Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
    Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
    Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
    Gaziano JM; Brotons C; Coppolecchia R; Cricelli C; Darius H; Gorelick PB; Howard G; Pearson TA; Rothwell PM; Ruilope LM; Tendera M; Tognoni G;
    Lancet; 2018 Sep; 392(10152):1036-1046. PubMed ID: 30158069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.
    Hill NR; Lasserson D; Thompson B; Perera-Salazar R; Wolstenholme J; Bower P; Blakeman T; Fitzmaurice D; Little P; Feder G; Qureshi N; Taal M; Townend J; Ferro C; McManus R; Hobbs FR
    Trials; 2014 May; 15():160. PubMed ID: 24886488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial.
    Hopley CW; Kavanagh S; Patel MR; Ostrom C; Baumgartner I; Berger JS; Blomster JI; Fowkes FGR; Jones WS; Katona BG; Mahaffey KW; Norgren L; Rockhold FW; Hiatt WR
    Vasc Med; 2019 Oct; 24(5):422-430. PubMed ID: 31339474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
    Timmis A; Rapsomaniki E; Chung SC; Pujades-Rodriguez M; Moayyeri A; Stogiannis D; Shah AD; Pasea L; Denaxas S; Emmas C; Hemingway H
    BMJ; 2016 Jun; 353():i3163. PubMed ID: 27334486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
    Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici MG; Mattle HP; Rothwell PM;
    Cerebrovasc Dis; 2009; 27(5):509-18. PubMed ID: 19372653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
    Joseph P; Roshandel G; Gao P; Pais P; Lonn E; Xavier D; Avezum A; Zhu J; Liu L; Sliwa K; Gamra H; Bangdiwala SI; Teo K; Diaz R; Dans A; Lopez-Jaramillo P; Prabhakaran D; Castellano JM; Fuster V; Rodgers A; Huffman MD; Bosch J; Dagenais GR; Malekzadeh R; Yusuf S;
    Lancet; 2021 Sep; 398(10306):1133-1146. PubMed ID: 34469765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease.
    Redfern J; Tu Q; Hyun K; Hollings MA; Hafiz N; Zwack C; Free C; Perel P; Chow CK
    Cochrane Database Syst Rev; 2024 Mar; 3(3):CD011851. PubMed ID: 38533994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.
    ; Davidson KW; Barry MJ; Mangione CM; Cabana M; Chelmow D; Coker TR; Davis EM; Donahue KE; Jaén CR; Krist AH; Kubik M; Li L; Ogedegbe G; Pbert L; Ruiz JM; Stevermer J; Tseng CW; Wong JB
    JAMA; 2022 Apr; 327(16):1577-1584. PubMed ID: 35471505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
    Squizzato A; Bellesini M; Takeda A; Middeldorp S; Donadini MP
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD005158. PubMed ID: 29240976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omega-6 fats for the primary and secondary prevention of cardiovascular disease.
    Hooper L; Al-Khudairy L; Abdelhamid AS; Rees K; Brainard JS; Brown TJ; Ajabnoor SM; O'Brien AT; Winstanley LE; Donaldson DH; Song F; Deane KH
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD011094. PubMed ID: 30488422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?
    Selak V; Jackson R; Poppe K; Kerr A; Wells S
    N Z Med J; 2018 Oct; 131(1484):19-25. PubMed ID: 30359352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular Protection of Aspirin in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.
    Chen T; Deng Y; Gong R
    Curr Vasc Pharmacol; 2024; 22(4):287-296. PubMed ID: 37259222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
    Kamal AK; Naqvi I; Husain MR; Khealani BA
    Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD008076. PubMed ID: 21249700
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.